Cancer Center Administration provides the overall administrative services that further the research and clinical missions of the P30 support grant. Administration has been extensively reorganized to address prior critiques, and to optimize its new position in the matrix Cancer Center formed following the December 2007 merger of the formerly independent CTRC with UTHSCSA. The new Associate Director of Administration has specific responsibilities commensurate with a senior leadership position within the Cancer Center. Administration provides a variety of critical functions in support of P30 operations, including: 1) providing oversight and coordination of P30-supported programs and shared resources, 2) serving as the direct liaison for, and supporting and coordinating the functions and meetings of key scientific and oversight committees, such as the Executive Committee, the Internal Advisory Committee, the External Advisory Board, program member meetings, and scientific retreats, 3) determining policy needs, and writing and implementing those policies for programs and shared resources, 4) providing financial accounting for all P30-related activities ncluding programs, shared resources, pilot programs, seminars, retreats and other activities, 5) coordinating and documenting use of P30-related laboratory, clinical and administrative space, 6) coordinating and overseeing P30-funded personnel, 7) coordinating communications among Cancer Center investigators and leadership, and UTHSCSA personnel, 8) serving as liaison with, and coordinator for funding sources including UTHSCSA and local and national agencies, 9) working closely with the Office of Research Administration to help ensure that clinical protocols and Material Transfer Agreements are executed, documented and maintained to appropriate standards and aligned well with UTHSCSA standards, and 10) coordinating informational communications between P30-supported scientific and clinical research arms and UTHSCSA, the region and the nation. Cancer Center Administration activities do not overiap with administrative functions supported elsewhere in the CTRC or in UTHSCSA, maximizing economies of scale.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-19
Application #
8320956
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
19
Fiscal Year
2011
Total Cost
$112,153
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications